Kornimate/medical-research-clean huggingface dataset:
fluvastatin versus hepatitis c virus

Conditions: Hepatitis C

Summary: this is a dose finding and efficacy trial for fluvastatin versus hepatitis c.

four different oral doses of fluvastatin will be used for 14 days and the viral load of hepatitis c will be measured weekly. this has been extended to different doses for 9-12 weeks.

Eligibility criteria:
inclusion criteria: * hcv rna positive exclusion criteria: * testing positive for alcohol or marijuana

Keywords: hepatitis c fluvastatin
changes in stem cells of the colon in response to increased risk of colorectal cancer

Conditions: Colorectal Cancer

Summary: colorectal cancer is a common disease worldwide. increasing evidence is demonstrating that colorectal cancers arise from 'cancer stem cells.' stem cells in the colon reside at the bottom of thousands of microscopic crypts throughout the wall of the colon. they create all the cells lining the bowel wall. these cells are created in the base of the crypt and ascend to the top acquiring the characteristics of mature cells of the bowel wall as they ascend. it is now thought that colorectal cancer cells arise from stem cells where the genetic material regulating growth and division of the stem cell has become defective. this leads to unregulated production of cells which in turn have defective genetic information and cancer formation. prior studies have demonstrated that the earliest changes before a cancer develops are changes in cellular proliferation. now that reliable markers to identify stem cells have been found, the researchers aim to investigate stem cell numbers and changes in distribution in those at normal risk of colorectal cancer and those at higher risk. the researchers hypothesise that changes in cellular proliferation at the top of the crypt in individuals at higher risk of colorectal cancer are due to a change in the number of stem cells in the crypt base.


Eligibility criteria:
inclusion criteria: * referred for endoscopy at participating centre exclusion criteria: * age \ 85 * familial polyposis syndrome * lynch syndrome * known colorectal tumour * previous colorectal resection * pregnancy * chemotherapy in last 6 months * therapy with aspirin/other nonsteroidal anti-inflammatory drug (nsaid) * other immunosuppressive medication * incomplete left sided examination * colorectal carcinoma found at endoscopy * iatrogenic perforation at endoscopy * colorectal cancer on histology * microscopic colitis on histology for the colitis group * simple clinical colitis activity index (sccai) score \> 5

Keywords: colorectal cancer stem cells ulcerative colitis polyps
recollect the game: a novel treatment for executive functioning deficits in adults with adhd

Conditions: Adult ADHD

Summary: adults who have attention deficit hyperactivity disorder (adhd) suffer from significant occupational, academic and social problems, many of which are believed to be a result of problems with executive functioning. executive functioning refers to a group of neuro-psychological functions which include sustained attention, working memory, verbal fluency, as well as motor and mental processing speed. individuals with adhd have been shown to have deficits in executive functioning independent of iq, co-occurring psychiatric disorders, gender, and adhd subtype. "recollect" is an application (app) based working memory training video game where participants conduct 3-different adaptive working memory tasks. in each of these tasks participants are presented with a set of stimuli to be remembered while playing a simple platform game where they help navigate an astronaut across the screen and dodge obstacles. recollect has been designed for all age groups to an interesting, fun and effective brain-training activity. the memory tasks included in the game have been independently shown to improve working memory in a manner that transfers to untrained tasks. the purpose of this study is to evaluate the effects of playing recollect versus tetris for 20 minutes per day, 5 days per week over a 4 week period, on executive functioning deficits in individuals who have adult adhd.

the primary objective is to evaluate the effects of playing recollect versus tetris for 20 minutes per day, 5 days per week over a 4 week period, on executive functioning deficits in individuals who have adult attention deficit hyperactivity disorder (adhd).consenting participants will be screened using the mini international neuropsychiatric interview for dsm-5 (mini) to confirm adhd diagnosis. participants will be asked to download either recollect or tetris on their own mobile device. following a training/orientation session, they will be asked to spend 20 minutes per day at least 5 days per week playing recollect or tetris over a 4 week period. at week 4, study staff will check the time log on the recollect/tetris app to confirm how much time was spent playing the game. participants will be asked to complete two adhd symptom severity scales, as well as app-based neurocognitive testing at baseline (week 0) and endpoint (week 4).

Eligibility criteria:
inclusion criteria: 1. males and females aged 18 and older who own a mobile device such as a smartphone or tablet. 2. current diagnosis of adult adhd, at any stage of treatment. 3. comorbid psychiatric conditions will be allowed. 4. medication or psychotherapy must have been stable (no dose changes) for 4 weeks prior to study participation. 5. must be able to read, write and understand english. exclusion criteria: 1. participant does not own a smartphone or tablet. 2. no dose changes during the 4 week study period. 3. no initiation of new psychological therapy or counselling during the 4 week study period.

Keywords: adhd executive functioning game
ppg to predict ejection fraction and other echographic data in the general population

Conditions: Valvular Heart Disease; Pericardial Disease; Cardiomyopathies

Summary: the investigators are aiming to investigate the association between ejection fraction (ef) determined by echocardiography and signals obtained from photoplethysmography (ppg) in the general population. the investigators are also aiming to investigate the association between blood pressure and signals obtained from ppg in the general population. finally, the investigators are also aiming to investigate the association between signals obtained from ppg in the general population to cardioechographic findings such as, valvular heart disease, structural heart diseases, cardiomyopathies, pericardial disease etc.

the investigators are proposing a cross-sectional cohort study, where any individual, 18 years old or older, scheduled for an echocardiography at tulane university's outpatient cardiology clinic can be included. after consenting participants, information on their demographics, personal health habits, medications, and medical history will be collected via reviewing, their electronic medical health records. all participants will undergo an echocardiography as part of their routine medical care by their treating physician. important echocardiographic findings will be noted such as, ef, valvular heart disease, pericardial disease, cardiomyopathies and structural heart disease. additionally, ppg recordings will be collected simultaneously while performing echography using the biostrap wristband. the investigators will analyze the association between each echographic imaging feature, and the ppg waveform obtained. ppg waveform features will be used to develop a predictive model capable of calculating an estimate of ventricular ejection fraction without echocardiography. all echocardiograms will be performed by experienced operators at tulane medical center facilities. the study will occur at a single study site tulane medical center and clinics, with appropriate facilities and equipment to conduct the study accurately and safely. an experienced echocardiogram technician or cardiology fellow will collect the ppg recordings using the biostrap application. de-identified echocardiogram reports, including information on lvef will be matched with the participant's pulse report.

Eligibility criteria:
inclusion criteria: * male or female aged18 years or older. * patients scheduled to undergo an echocardiogram at tulane medical center. exclusion criteria: * participants under 18 years of age. * participants with cognitive impairments. * participants with a physical inability to wear the biostrap during the echocardiogram. * individuals who cannot read, speak, and/or understand english.

Keywords: structural heart disease photoplethysmography ejection fraction
apatinib for advanced sarcoma: results from multiple institutions' off-label use

Conditions: Efficacy; Toxicity

Summary: anti-angiogenesis tyrosine kinase inhibitors (tkis) have been proved to show promising effects on prolonging progression-free survival (pfs) for advanced sarcoma after failure of standard multimodal therapy. methylsulfonic apatinib is one of those tkis which specifically inhibits vegfr-2. this study summarizes the experience of three peking university affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.

the investigators retrospectively analysed files of patients with advanced sarcoma not amenable to curative treatment, who were receiving an apatinib-containing regimen between june 1, 2015 and december 1, 2016. fifty-six patients were included: 22 osteosarcoma, 10 ewing's sarcoma, 3 chondrosarcoma and 21 soft tissue sarcoma.

Eligibility criteria:
inclusion criteria: * 1) histologically confirmed high-grade sarcoma; * 2) initial treatment in the orthopedic oncology departments of the three affiliated hospitals of peking university; * 3) tumors not amenable to curative treatment or inclusion in clinical trials; * 4) unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy; * 5) measurable lesions according to response evaluation criteria for solid tumors (recist1.1) \[8\]; * 6) eastern cooperative oncology group performance status 0 or 1 \[9\]; and 7) acceptable hematologic, hepatic, and renal function. exclusion criteria: * had been previously exposed to other tkis; * had central nervous system metastasis; * had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia; * had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on; * had pleural or peritoneal effusion that needs to be handled by surgical treatment; * combined with other infections or wounds * were pregnant or breastfeeding.

Keywords: apatinib tyrosine-kinase inhibitors osteosarcoma ewing sarcoma chondrosarcoma soft-tissue sarcoma
evaluation of a new radiotracer (64cu-dota-ae105) for diagnosing aggressive cancer with positron emission tomography

Conditions: Breast Cancer; Prostate Cancer; Urinary Bladder Cancer

Summary: the primary objective of the study is to test a new radiotracer called 64cu-dota-ae105 for pet imaging of upar (urokinase plasminogen activator receptor). the tracer has the potential of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and less aggressive tumors. this is a first in human study to test the radiotracer in cancer patients. the biodistribution and tumor uptake will be evaluated by repeated pet imaging (1,3 and 24 hours post injection).

the primary objective of the study is to test a new radiotracer called 64cu-dota-ae105 for pet imaging of upar (urokinase plasminogen activator receptor). the tracer has the potential of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and less aggressive tumors. this is a first in human study to test the radiotracer in cancer patients. the biodistribution and tumor uptake will be evaluated by repeated pet imaging (1,3 and 24 hours post injection). the primary end points are biodistribution and dosimetry of 64cu-dota-ae105. in addition, the quantitative uptake of 64cu-dota-ae105 in tumors and expression of upar in tumor tissue obtained by surgery or biopsies (either 14 days before (only biopsies) or after the pet scans) will be compared to validate the image-derived data on upar expression

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cancer of prostate, breast or urinary bladder * capable of understanding and giving full informed consent exclusion criteria: * pregnancy * lactation * contraindication for the use of intravenous ct contrast-agencies * claustrophobia * other current/or former diagnosed cancers, except non melanoma skin cancer or carcinoma in situ cervicis uteri

Keywords: positron emission tomography uroplasminogen plasminogen activator receptor breast cancer prostate cancer urinary bladder cancer biodistribution radiation exposure
evaluation and implementation of new biomarkers and algorithms for diagnosis of ovarian cysts/tumors in the pelvis

Conditions: Ovarian Neoplasms; Diagnoses Disease; Biomarkers; Algorithms

Summary: this study evaluates the biomarkers ca125 and he4 and the algorithms rmi and roma on a normal population in the western region of sweden. the aim is to improve diagnosis of ovarian cancer. if the investigators observe a clear improvement in the early diagnosis of eoc, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of sweden.

the investigators are currently using ca125 and rmi in diagnosing patients with a pelvic cyst/tumor and referring them to tertiary centers for surgery in the western region of sweden. the diagnostic accuracy is unsatisfying why the investigators are evaluating he4 and roma as a complement, in combination or separately to improve diagnostic accuracy. the trial is based on a normal population cohort of patients included at all the hospitals in the region. the patients were included before surgery and the biomarkers analysed on serum samples withdrawn preoperatively. if the investigators observe a clear improvement in the early diagnosis of eoc, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of sweden.

Eligibility criteria:
inclusion criteria: * 18 years of age, understand spoken and written swedish information, admitted for surgery for a cyst/tumos in the pelvis exclusion criteria: * rejected participation, cytotoxic chemotherapy prior to surgery, rejected surgery, serum sample failure, already included at another hospital

Keywords: he4 ca125 rmi roma
short course primaquine for the radical cure of p. vivax - papua new guinea

Conditions: Vivax Malaria; G6PD Deficiency

Summary: significant gains have been made in reducing the overall burden of malaria worldwide, however these have been far greater for plasmodium falciparum than p. vivax. p. vivax remains a major obstacle to malaria control and elimination efforts, largely due to its ability to form dormant liver stages (hypnozoites) that allows it to escape detection and treatment. importantly, they are susceptible only to 8 aminoquinolines such as primaquine. however, primaquine is associated with risk of haemolysis in individuals with a genetic condition, called glucose-6-phosphate dehydrogenase (g6pd) deficiency. additionally, the recommended 14-day prolonged treatment regimen is associated with poor treatment adherence, hence ineffective primaquine treatment. innovative solutions to the radical cure of both the blood and liver stages of p. vivax are urgently required. the png national department of health has requested a pragmatic study of the feasibility and cost-effectiveness of implementing point-of-care g6pd testing followed by high-dose, short-course primaquine treatment regimens for patients with p. vivax malaria. this revised case management is to be combined with practicable enhancements to patient education, supervision, malariometric surveillance and pharmacovigilance. this will be a before-after longitudinal health facility-based study implemented at napapar and mugil health centres and baro and wirui clinics. a staged approach for the implementation of the revised case management strategy will be used, including patient education and counselling, community-based clinical review, with mixed methods evaluation.


Eligibility criteria:
inclusion criteria: * patients with vivax malaria exclusion criteria: * patients who are pregnant * patients who are breastfeeding * patients with a hb \<8g/dl * patients with a previous adverse reaction to primaquine * patient with severe malaria

Keywords: primaquine
cognitive intervention after a brain tumor

Conditions: Brain Tumors

Summary: this study evaluates the feasibility and utility of two behavioural programs designed to reduce cognitive impairments secondary to brain tumors and/or their treatment. one-third of participants will complete training in either program, with the remaining third a wait-list control group.

cognitive impairments (including problems with attention, memory or executive functions) are common in people with brain tumors, as a result of the disease and/or treatment effects. these deficits, even when relatively mild, can interfere with interpersonal relationships, occupational activities, functional independence, and quality of life. they may also contribute to caregiver burden. building on research in other cognitively-impaired populations, in this study we compare two behavioural interventions. the brain training (bt) and brain health (bh) interventions each offer a structured yet client-centered program through 8 weekly individual treatment sessions and between-session exercises. contents include mindfulness practice, strategy training, and supportive psychoeducation including counseling around lifestyle factors to promote brain functioning. using a prospective randomized controlled design, 54 brain tumor patients are being enrolled in one of three study arms: bt, bh, or standard care (wait-list control). a battery of outcome measures is being administered (1) prior to intervention, (2) after the 8-week behavioural intervention (or wait-list) period, and (3) after an additional 4 months to evaluate longer-term outcomes. analyses of variance will examine treatment effects, with regression analyses to explore moderating effects of participant demographics, severity of baseline cognitive impairment, and tumor and treatment factors (e.g., tumor location, radiation dose and distribution). results of this trial will lay the groundwork for implementation of evidence-based supportive care to reduce and manage cognitive impairments following a brain tumor.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. fluent in english 3. able to provide informed consent to all procedures 4. diagnosis of a brain tumor 5. indication of lasting post-treatment cognitive deficits (e.g., from clinical presentation, prior neuropsychological assessment, and/or self-report) 6. sufficient motor and sensory functioning to complete study activities 7. availability to complete all study activities 8. for patients treated with cranial radiation, at least 3 months post-radiation exclusion criteria: (1) comorbid neurological or psychiatric disorder or other medical condition suspected to influence cognition
serum procalcitonin level may predict acute kidney injury in icu patients with sepsis

Conditions: Acute Kidney Injury

Summary: the aim of this study is to examine if procalcitonin (pct) can be used for early prediction of aki septic patients in icu.

67 patients with sepsis were enrolled in this study. on admission, pct was measured together with serum creatinine, urea, and other inflammatory markers. quick sepsis-related organ failure assessment was calculated at the emergency department. patients were classified into those with acute kidney injury (aki) and non-aki groups.

Eligibility criteria:
inclusion criteria: * icu patients with sepsis exclusion criteria: * patient known to have end-stage kidney disease * patients on renal replacement therapy * patients without procalcitonin level within 24 hours from admission.
phase 3 evaluation of re-injection of nx-1207 for the treatment of benign prostatic hyperplasia (bph)(nx02-0022)

Conditions: Benign Prostatic Hyperplasia; BPH; Lower Urinary Tract Symptoms (LUTS); LUTS

Summary: this study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of nx-1207 given to subjects with benign prostatic hyperplasia (bph) who previously received an injection of nx-1207 in an earlier u.s. clinical trial of nx-1207.


Eligibility criteria:
inclusion criteria: * be male aged 45 or older. * sign an informed consent form. * be in good health. * received nx-1207 in a previous completed study (other than nx02-0020) or received nx-1207 or placebo in a concurrent u.s. study (nx02-0017 and nx02-0018) and completed their v10 (365 day) visit. * have prostate gland volume ≥ 25 ml (25 g). exclusion criteria: * surgery or minimally invasive surgical therapy (mist) for treatment of bph after first nx-1207 injection * post-void residual urine volume \> 200 ml * presence of a symptomatic median lobe of the prostate * history of use of self-catheterization for urinary retention. * urinary retention in the previous 12 months. * prostatitis * urinary tract infection more than once in the past 12 months * prostate or bladder cancer. * prostate-specific antigen (psa) ≥ 10 ng/ml * poorly controlled diabetes * history or evidence of illness or condition that may interfere with study or endanger subject * participation in a study of any investigational drug (other than nx-1207) or investigational device within the previous 90 days * use of specific prescribed medications that may interfere with study or endanger subject

Keywords: benign prostatic hyperplasia bph lower urinary tract symptoms luts luts secondary to bph luts/bph benign prostatic obstruction (bpo) bpo bladder outlet obstruction boo